Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Glenwood GossLesley Seymour

Abstract

PURPOSE This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Paclitaxel (200 mg/m(2)) and carboplatin (area under the serum concentration-time curve 6) were given every 3 weeks, with daily oral cediranib or placebo at 30 mg (first 45 patients received 45 mg). Progression-free survival (PFS) was the primary outcome of the phase II interim analysis; phase III would proceed if the hazard ratio (HR) for PFS < or = 0.77 and toxicity were acceptable. Results A total of 296 patients were enrolled, 251 to the 30-mg cohort. The phase II interim analysis demonstrated a significantly higher response rate (RR) for cediranib than for placebo, HR of 0.77 for PFS, no excess hemoptysis, and a similar number of deaths in each arm. The study was halted to review imbalances in assigned causes of death. In the primary phase II analysis (30-mg cohort), the adjusted HR for PFS was 0.77 (95% CI, 0.56 to 1.08) with a higher RR for cediranib than for placebo (38% v 16%; P < .0001). Cediranib patients had more hypertension, hypothyroidism, hand-foot syndrome, and GI toxicity. Hypoalbuminemia, age > or = 65 years, ...Continue Reading

References

Jan 3, 1990·Journal of the National Cancer Institute·J Folkman
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B BergmanM Sullivan
Dec 1, 1993·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·R T AndersonD Wilkin
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 7, 2006·Seminars in Oncology·Corey J Langer, Ronald B Natale
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joachim DrevsClemens Unger
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fernando Gomez-RiveraJeffrey N Myers
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jun 4, 2008·Annals of the New York Academy of Sciences·Marc G Achen, Steven A Stacker
Aug 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nasser Hanna
Dec 19, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Glenwood GossLesley Seymour
Feb 21, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric ChenLesley Seymour

❮ Previous
Next ❯

Citations

Jan 29, 2013·Targeted Oncology·Emilio BriaGiorgio Scagliotti
Feb 15, 2011·Current Oncology Reports·Pankaj Bhargava, Murray O Robinson
Jan 30, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M Majem, C Pallarès
Mar 8, 2013·Nature Medicine·Bernhard Polzer, Christoph A Klein
Nov 10, 2013·Nature Medicine·Liling WanYibin Kang
Nov 12, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jason DolesMichael T Hemann
Oct 20, 2011·Journal of the National Cancer Institute·Ole-Petter Riksfjord HamnvikEllen Marqusee
Jan 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Osamu TakahashiMichael S O'Reilly
Jun 22, 2011·OncoTargets and Therapy·Marc S Ballas, Abraham Chachoua
Apr 3, 2013·Archives of Pathology & Laboratory Medicine·Kirtee RapariaMinesh P Mehta
Dec 7, 2013·Pathology Oncology Research : POR·Nora BittnerLajos Géczi
Jun 1, 2012·Future Oncology·Bruno GoriFilippo de Marinis
Jul 27, 2012·Future Oncology·Marina SahadePaulo M Hoff
Dec 14, 2011·Revue des maladies respiratoires·S MarcoF Barlesi
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C TwelvesJ H Schiller
Oct 12, 2011·Investigational New Drugs·George R Blumenschein
Aug 11, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T KatoH Mishima
Mar 24, 2012·Expert Opinion on Therapeutic Targets·Millie Das, Heather Wakelee
Jul 18, 2014·Expert Opinion on Pharmacotherapy·Erika RijavecFrancesco Grossi
Mar 5, 2013·Expert Opinion on Investigational Drugs·Judy W King, Siow-Ming Lee
Jun 13, 2015·Expert Opinion on Investigational Drugs·Sara PilottoEmilio Bria
May 4, 2011·Expert Opinion on Investigational Drugs·Kanwal Pratap Singh Raghav, George R Blumenschein
Jan 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rebecca S HeistUNKNOWN Alliance for Clinical Trials in Oncology
Nov 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tetsuya Mitsudomi, Hirohito Tada
Nov 28, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Millie Das, Heather Wakelee
Dec 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Grace K DyAlex A Adjei
Aug 27, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Silvia NovelloDavid R Spigel
Oct 26, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Janakiraman SubramanianRamaswamy Govindan
Oct 26, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Millie Das, Heather Wakelee
Jan 7, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Giorgio V ScagliottiThierry Lechevalier
Oct 4, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Linda L GarlandDavid R Gandara

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Giorgio Vittorio ScagliottiNasser Hanna
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Martin ReckChristian Manegold
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nasser AltorkiDavid F Yankelevitz
© 2022 Meta ULC. All rights reserved